Skip to Content
A26 / P26
NCODA Oncology and Hematology Meeting Abstracts | Volume 2 | Supplement 1
Publication Date: April 7, 2026

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair–deficient or microsatellite instability–high primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Authors:

Matthew A. Powell1, Oleksandr Zub2, Lucy Gilbert3, Anthoula Koliadi4, Lyndsay J. Willmott5, Destin Black6, Graziana Ronzino7, Sudarshan Sharma8, Martina Gropp- Meier9, Lisa M. Landrum10, Anna M. Thijs11, Elizabeth Lokich12, Michael A. Gold13, Sarah E. Gill14, Carolyn McCourt15, Ilana Cass16, Matthew Grimshaw17, Laura Austin18, Mitchell I. Edelson19, Trine Nøttrup20

Organization / Company:

1Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA;2Chernihiv Medical Center of Modern Oncology, Chernihiv Regional Council, Chernihiv, Ukraine; 3Division of Gynecologic Oncology, Research Institute, McGill University Health Centre, Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada; 4Department of Gynecologic Oncology, Uppsala University Hospital, Uppsala, Sweden, and Nordic Society of Gynecologic Oncology (NSGO), Uppsala, Sweden; 5Arizona Center for Cancer Care, Phoenix, AZ, USA; 6Willis-Knighton Cancer Center, Willis-Knighton Health System, Gynecologic Oncology Associates, Shreveport, LA, USA; 7Department of Oncology, Ospedale Vito Fazzi, Lecce, Italy; 8Department of Obstetrics/Gynecology, AMITA Health Adventist Medical Center, Hinsdale, IL, USA; 9AGO Study Group, Wiesbaden, and Oberschwabenklinik, St. Elisabethen-Klinikum, Ravensburg, Germany; 10Indiana University Health & Simon Cancer Center, Indianapolis, IN, USA; 11Department of Medical-Oncology, Catharina Hospital, Eindhoven, the Netherlands; 12Women and Infants Hospital of Rhode Island, Providence, RI, USA; 13Department of Gynecologic Oncology, Oklahoma Cancer Specialists and Research Institute, Tulsa, OK, USA; 14St. Joseph’s/Candler Gynecologic Oncology & Surgical Specialists, Candler Hospital, Savannah, GA, USA; 15Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, Washington University in St Louis, St Louis, MO, USA; 16Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 17GSK, London, UK; 18GSK, Collegeville, PA, USA; 19Hanjani Institute for Gynecologic Oncology, Jefferson Abington Hospital, Willow Grove, PA, USA; 20Department of Oncology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, and NSGO, Copenhagen, Denmark

NCODA Oncol Hematol Meet Abstr. 2026;2(suppl 1):abstr 26.

Background:

In Part 1 of the phase 3 RUBY trial (NCT0-3981796), dostarlimab+carboplatin-paclitaxel (CP) demonstrated statistically significant and clinically meaningful improvements in progression- free (PFS) and overall survival (OS) compared with CP alone among patients with primary advanced or recurrent endometrial cancer (pA/R EC). Here, we report updated efficacy and safety data with 4 years of follow-up in patients with mismatch repair-deficient/microsatellite instability-high (dMMR/ MSI-H) pA/R EC. In addition, complementary conditional survival analyses (cOS/cPFS) are presented to provide clinically relevant, prognostic insights into long-term survival potential for patient counseling.

Objectives:
  • Describe long-term progression-free survival and overall survival in patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in Part 1 of the RUBY trial.
  • Describe the probability of long-term survival using conditional overall survival, a tool that may aid clinicians in counseling patients on their likelihood of long-term survival in the era of immunotherapy in endometrial cancer.
Methods:

Patients were randomized 1:1 to receive dostarlimab+ CP (n=53) or placebo+CP (n=65) every 3 weeks every 3 weeks (Q3W) (6 cycles) followed by dostarlimab or placebo monotherapy Q6W for up to 3 years or until disease progression. At median follow-up of 55.6 months, descriptive analyses of OS and PFS and post-hoc analyses of cOS and cPFS were conducted in the dMMR/MSI-H pA/R EC population.

Results:

Dostarlimab+CP demonstrated sustained OS (hazard ratio (HR), 0.34) and PFS (HR, 0.30) benefits at the 4-year analysis versus (vs) placebo+CP; only 4 additional progression events occurred during 2.5 years of additional follow-up since the first interim analysis. Four-year PFS rates of 57.9% vs 15.7% were consistent with reported 2-year PFS rates of 61.4% vs 15.7% for dostarlimab+CP vs placebo+ CP, respectively. Median OS was not reached (NR) at 4 years for dostarlimab+CP arm vs 32.8 months for placebo+CP; dostarlimab+CP resulted in a 4-year OS rate of 72.8% vs 40.3% for placebo+CP. Median duration of response (DOR) was NR for dostarlimab+CP and 4.8mo for placebo+CP; 4-year DOR rate was 54.8% for dostarlimab+ CP and 10.6% for placebo+CP. cOS analyses revealed the probability of remaining alive for an additional year increased with each subsequent year of survival. Patients alive and progression-free at 1-year had an almost 97% probability of remaining progression-free at 3 years (additional 2 years). Similar trends were observed at 2-year and 3-year cOS and at 2-year cPFS. No new safety signals were observed with additional follow-up.

Conclusions:

Substantial and unprecedented long-term survival benefits were demonstrated with dostarlimab+CP vs placebo+CP in patients with dMMR/MSI-H pA/R EC at 4 years. Dostarlimab+CP remains the only combination of immunotherapy and chemotherapy to demonstrate statistically significant and clinically meaningful OS benefits. Conditional survival estimates indicated that nearly all patients who remained alive and progression-free with dostarlimab+CP at 1 year remained so at 3 years, providing a powerful tool for patient counseling. Together, these data reinforce the use of dostarlimab+CP as standard-of-care and offer the potential for curative intent for patients with pA/R dMMR/MSI-H EC.

Funding: GSK.

Prior Presentations:

Presented at the Society of Gynecological Oncology (SGO) Annual Meeting on Women’s Cancer 2026, April 10–13, San Jaun, Puerto Rico.

A26 / P26